Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer King Fahad Medical City Completed Docetaxel/Cisplatin and Bevacizumab 3 Version 1.3 date 6 may 2012 KFMC
A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR) Novartis Completed Brolucizumab 3 CRTH258D2301 DESH
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation anssen-Cilag International NV Completed paliperidone 3 R092670SCH3015 JPH
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' AstraZeneca Completed Budesonide + Formoterol VS. Budesonide + Terbutaline 3 D589SC00003 AFH-DH
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Alcon Completed Travoprost 0.004% / Timolol 3 C-12-008 KKESH
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma Novartis Terminated QAW039/Fevipiprant 3 CQAW039A2315 KFMC
A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma Novartis Terminated QAW039/Fevipiprant 3 CQAW039A2315 KFMC
A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants Novartis Completed Everolimus + reduced tacrolimus VS.Tacrolimus 3 CRAD001H2307 KFSH & RC-R
“MERS-CoV Infection Treated with a Combination of Lopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial)” KAIMRC Completed Kaletra 3 RC15/142/R NGHA-R
"RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity" Novartis Completed Ranibizumab 3 CRFB002H2301E1 KFSH & RC-R
View 441 - 450 From 804